Literature DB >> 3020297

Natural killer cell activity and head and neck cancer: a clinical assessment.

S P Schantz, E J Shillitoe, B Brown, B Campbell.   

Abstract

In 127 patients with squamous cell carcinoma of the upper aerodigestive system, an assessment of natural killer (NK) cell function was performed. The mean lytic unit (LU) value of this cancer population was noted to be less than the mean value of 67 age-matched controls assessed concurrently. The major determinant of cytolytic function was related to the growth pattern of the tumor. Increased NK cell function was observed in patients with lesions that were more locally or regionally aggressive, i.e., that infiltrated surrounding anatomic structures. The magnitude of NK cell response also correlated with increased amounts of circulating IgG immunoglobulin to herpes simplex virus-type 1-associated antigens; elevated IgG levels were also associated with locally aggressive lesions. The clinical significance of NK cell activity in these patients is shown by its relationship to disease-free prognosis. Patients with elevated NK activity followed for a mean of 12 months had an improved disease-free survival as compared to the survival of the remaining population. Furthermore, NK LU values were not reflected in standard staging methods, which suggests that the measurement of NK cell function represents an independent prognostic parameter in the patient with head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020297

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  37 in total

1.  IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Authors:  B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2012-01-20       Impact factor: 6.968

Review 2.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

Review 3.  Biological significance of autologous tumor-killing activity and its induction therapy.

Authors:  A Uchida
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 4.  Biologic markers, cellular differentiation, and metastatic head and neck cancer.

Authors:  S P Schantz
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

5.  Immunotherapy in new pre-clinical models of HPV-associated oral cancers.

Authors:  Francesca Paolini; Silvia Massa; Isabella Manni; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

Review 6.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

7.  The head and neck cancer immune landscape and its immunotherapeutic implications.

Authors:  Rajarsi Mandal; Yasin Şenbabaoğlu; Alexis Desrichard; Jonathan J Havel; Martin G Dalin; Nadeem Riaz; Ken-Wing Lee; Ian Ganly; A Ari Hakimi; Timothy A Chan; Luc Gt Morris
Journal:  JCI Insight       Date:  2016-10-20

8.  Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer cell immunity for clinical use in cancer.

Authors:  Hyung Gun Maeng; Su Jin Lee; Yun A Lee; Hye Jeong Lee; Young Joo Kim; Jong Kyun Lee; Jae Cheol Kim; Joungbum Choi
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

9.  Responses of killer cells in head and neck cancer patients.

Authors:  S Fujieda; H Saito; T Hoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

10.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.